SNPHF (Santen Pharmaceutical Co) Insider Ownership: 0.00 % (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNPHF Santen Pharmaceutical Co Ltd SNPHF
73 GF Score
Price $13.05
GF Value $10.46
Valuation Modestly Overvalued
View Full Analysis

What is Santen Pharmaceutical Co Insider Ownership?

Santen Pharmaceutical Co SNPHF +4.40% 73 Insider Ownership is 0.00 % as of Aug. 23, 2026. GuruFocus rates SNPHF with a GF Score™ of 73/100 and a GF Value™ of $10.46 (Modestly Overvalued).

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Santen Pharmaceutical Co's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Santen Pharmaceutical Co's Institutional Ownership is 34.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Santen Pharmaceutical Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Santen Pharmaceutical Co Insider Ownership Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Insider Ownership Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Santen Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SNPHF
73GF Score
Santen Pharmaceutical Co Ltd SNPHF
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Santen Pharmaceutical Co (SNPHF) has a Insider Ownership of 0.00 % as of Aug. 23, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Insider Ownership too high?
Santen Pharmaceutical Co's current Insider Ownership is 0.00 %. Overall, Santen Pharmaceutical Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Insider Ownership compare to LLY and JNJ?
Santen Pharmaceutical Co's Insider Ownership of 0.00 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.46, compared to a current price of $13.05 — trading 24.8% above its estimated fair value. The current Insider Ownership is 0.00 %. Santen Pharmaceutical Co's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Insider Ownership is 0.00 % as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 24.8% above its estimated GF Value™ of $10.46. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Insider Ownership: 0.00 %
  • GF Value™: $10.46 vs. price of $13.05 (24.8% above fair value)
  • GF Score™: 73/100

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
73GF Score

Get the complete analysis for SNPHF

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.46
GF Value